US FDA sets denosumab panel review for August
This article was originally published in Scrip
Executive Summary
The US FDA's reproductive health drugs advisory panel will review Amgen's fully human monoclonal antibody denosumab (proposed trade name Prolia) on August 13th for osteoporosis and bone loss resulting from cancer treatment.